Novartis (NYSE:NVS) Shares Gap Up – Here’s Why

Novartis AG (NYSE:NVS) gapped up before the market opened on Tuesday . The stock had previously closed at $152.06, but opened at $162.15. Novartis shares last traded at $161.64, with a volume of 1,164,231 shares traded.

Key Stories Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Remibrutinib meets Phase III goals: Novartis said the REMODEL-1 and REMODEL-2 trials met their primary endpoints, with remibrutinib significantly reducing annualized relapse rates versus teriflunomide. The drug also performed favorably on secondary measures, including MRI lesion reductions, and a combined analysis indicated a clinically meaningful delay in disability progression. Novartis plans to present detailed data and seek regulatory approvals globally, strengthening the drug’s potential as a future growth product. Novartis’ oral multiple sclerosis drug meets main goal in late stage studies
• Positive Sentiment: Large-market opportunity supports investor optimism: The apparent superiority over an established multiple sclerosis treatment, combined with a favorable safety profile, improves the commercial prospects for remibrutinib and provides a positive read-through for Novartis’ pipeline. Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug
• Neutral Sentiment: Mixed institutional and options signals: Recent filings show both notable additions and reductions by large investors, while put-option activity was unusually high. These positioning indicators may reflect hedging or heightened volatility rather than a clear change in long-term sentiment.
• Neutral Sentiment: Minor earnings-estimate reduction: Erste Group Bank modestly lowered its FY2027 EPS forecast to $9.80 from $9.82, a change too small to materially alter the investment outlook. Erste Group Bank Forecasts Reduced Earnings for Novartis
• Negative Sentiment: Autoimmune cell-therapy trials paused: Novartis halted eight studies of experimental rap-cel after three patient deaths. The pause creates safety concerns and could delay or reduce the value of this portion of the pipeline, although the impact was overshadowed by the remibrutinib data. Novartis pauses autoimmune cell therapy studies after deaths

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Citigroup reissued a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a research report on Friday, July 24th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Novartis currently has an average rating of “Hold” and an average target price of $141.20.

Novartis Trading Up 5.9%

The stock’s 50-day moving average price is $155.14 and its 200 day moving average price is $153.72. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. The firm has a market capitalization of $307.41 billion, a PE ratio of 24.31, a price-to-earnings-growth ratio of 2.64 and a beta of 0.45.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The firm had revenue of $14.95 billion during the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%. On average, sell-side analysts expect that Novartis AG will post 8.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Highland Investment Advisors LLC bought a new stake in shares of Novartis in the 2nd quarter valued at about $25,000. Evolution Wealth Management Inc. boosted its stake in shares of Novartis by 552.0% during the second quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock valued at $26,000 after purchasing an additional 138 shares in the last quarter. Atlatl Advisers LLC purchased a new position in Novartis during the second quarter valued at approximately $26,000. Archer Investment Corp raised its stake in Novartis by 93.0% in the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock worth $25,000 after buying an additional 80 shares in the last quarter. Finally, CrossGen Wealth LLC bought a new position in Novartis in the fourth quarter worth approximately $28,000. 13.12% of the stock is currently owned by institutional investors.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.